Olema Oncology to Participate in Upcoming Investor Conferences in June
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences:
Jefferies Global Healthcare Conference
Date: Wednesday, June 5, 2024, at 2:00 p.m. ET
Location: Marriott Marquis in New York, NY
Format: Fireside Chat
Goldman Sachs 45th Annual Global Healthcare Conference
Date: Wednesday, June 12, 2024, at 11:20 a.m. ET
Location: Loews Miami Beach Hotel in Miami, FL
Format: Fireside Chat
Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at . The webcasts will be archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at .
Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
